Join the Dulaglutide group to help and get support from people like you.
Dulaglutide News
ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM
FRIDAY, April 4, 2025 – For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and...
GLP-1 RAs Reduce Risk for Clinically Important Kidney, CVD Outcomes
FRIDAY, Dec. 6, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular disease outcomes in individuals with type 2 diabetes,...
Stroke Guidelines Updated, With Focus on Women and GLP-1s
MONDAY, Nov. 25, 2024 – Women, especially those who had high blood pressure during pregnancy or entered menopause before age 45, are among those with a greater risk for stroke. They and other...
Glucagon-Like Peptide-1 Receptor Agonists May Reduce Alcohol Consumption
THURSDAY, Nov. 21, 2024 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov....
More Evidence That GLP-1 Meds Curb Alcohol Abuse
FRIDAY, Nov. 15, 2024 – There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to curb problem...
Guidance Issued for Safe Use of GLP-1 RAs in the Perioperative Period
TUESDAY, Nov. 5, 2024 – In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, recommendations are presented for the safe use of...
ACG: GLP-1 RAs Tied to Lower Risk for Early-Onset Colorectal Cancer
FRIDAY, Nov. 1, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of...
FDA Medwatch Alert: FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection ...
Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
TUESDAY, Oct. 15, 2024 – For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduced risk for suicidal ideation or attempts, according to...
GLP-1 RA Use Linked to Retained Gastric Contents During Endoscopies
FRIDAY, Oct. 4, 2024 – Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic...
Risk for Dementia Similar With SGLT2 Inhibitors, Dulaglutide in T2DM
MONDAY, Aug. 26, 2024 – For older adults with type 2 diabetes, the risk for dementia seems similar with sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide 1 receptor...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
Further information
Related condition support groups
Cardiovascular Risk Reduction, Diabetes, Type 2, Weight Loss (Obesity / Overweight)